• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cardiac risk stratification in cancer patients: A longitudinal patient –patient network analysis
by Yuan Hou, Yadi Zhou, Muzna Hussain, G. Thomas Budd, Wai Hong Wilson Tang, James Abraham, Bo Xu, Chirag Shah, Rohit Moudgil, Zoran Popovic, Chris Watson, Leslie Cho, Mina Chung, Mohamed Kanj, Samir Kapadia, Brian Griffin, Lars Svensson, Patrick Collier, Feixiong Cheng BackgroundCardiovascular disease is a leading cause of death in general population and the second leading cause of mortality and morbidity in cancer survivors after recurrent malignancy in the United States. The growing awareness of cancer therapy –related cardiac dysfunction (CTRCD) has led to an emerging field of cardio-oncology; yet, there is limited k...
Source: PLoS Medicine - August 2, 2021 Category: Internal Medicine Authors: Yuan Hou Source Type: research